174 related articles for article (PubMed ID: 35139768)
1. Acetylshikonin suppresses diffuse large B-Cell Lymphoma cell growth by targeting the T-lymphokine-activated killer cell-originated protein kinase signalling pathway.
Cui J; Guo R; Wang Y; Song Y; Song X; Li H; Song X; Li J
Bioengineered; 2022 Feb; 13(2):4428-4440. PubMed ID: 35139768
[TBL] [Abstract][Full Text] [Related]
2. Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase.
Zhao R; Choi BY; Wei L; Fredimoses M; Yin F; Fu X; Chen H; Liu K; Kundu JK; Dong Z; Lee MH
Br J Pharmacol; 2020 May; 177(10):2303-2319. PubMed ID: 31985814
[TBL] [Abstract][Full Text] [Related]
3. Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer.
Zhao R; Huang H; Choi BY; Liu X; Zhang M; Zhou S; Song M; Yin F; Chen H; Shim JH; Bode AM; Dong Z; Lee MH
Phytomedicine; 2019 Aug; 61():152813. PubMed ID: 31035049
[TBL] [Abstract][Full Text] [Related]
4. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
5. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
6. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
7. Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Herbert KJ; Puliyadi R; Prevo R; Rodriguez-Berriguete G; Ryan A; Ramadan K; Higgins GS
Cell Death Differ; 2021 Apr; 28(4):1333-1346. PubMed ID: 33168956
[TBL] [Abstract][Full Text] [Related]
8. miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway.
Huang Y; Zou Y; Lin L; Ma X; Zheng R
Oncol Rep; 2019 Jan; 41(1):377-386. PubMed ID: 30365139
[TBL] [Abstract][Full Text] [Related]
9. Paeonol suppresses solar ultraviolet-induced skin inflammation by targeting T-LAK cell-originated protein kinase.
Xue P; Wang Y; Zeng F; Xiu R; Chen J; Guo J; Yuan P; Liu L; Xiao J; Lu H; Wu D; Pan H; Lu M; Zhu F; Shi F; Duan Q
Oncotarget; 2017 Apr; 8(16):27093-27104. PubMed ID: 28404919
[TBL] [Abstract][Full Text] [Related]
10. Scutellarin Suppresses RPMI7951 Melanoma Cell Proliferation by Targeting TOPK.
Mu X; Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S
Anticancer Agents Med Chem; 2021; 21(5):640-648. PubMed ID: 32781970
[TBL] [Abstract][Full Text] [Related]
11. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.
Zykova TA; Zhu F; Lu C; Higgins L; Tatsumi Y; Abe Y; Bode AM; Dong Z
Clin Cancer Res; 2006 Dec; 12(23):6884-93. PubMed ID: 17145805
[TBL] [Abstract][Full Text] [Related]
13. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Li Y; Yang Z; Li W; Xu S; Wang T; Wang T; Niu M; Zhang S; Jia L; Li S
Oncotarget; 2016 Feb; 7(6):6748-64. PubMed ID: 26745678
[TBL] [Abstract][Full Text] [Related]
14. TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin.
Jiang Y; Zhang J; Zhao J; Li Z; Chen H; Qiao Y; Chen X; Liu K; Dong Z
BMC Cancer; 2019 Dec; 19(1):1264. PubMed ID: 31888532
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells.
Abe Y; Matsumoto S; Kito K; Ueda N
J Biol Chem; 2000 Jul; 275(28):21525-31. PubMed ID: 10781613
[TBL] [Abstract][Full Text] [Related]
16. TOPK promotes the development of psoriasis and worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity.
Lu H; Huang Y; Ni X; Ma T; Chang T; Liu M; Li N; Lu P; Yuan P; Liu L; Shi F; Xiao J; Xiao H; Duan Q; Zhu F
J Eur Acad Dermatol Venereol; 2024 May; 38(5):851-863. PubMed ID: 38131517
[TBL] [Abstract][Full Text] [Related]
17. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
18. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
19. Xanthohumol inhibits non-small cell lung cancer via directly targeting T-lymphokine-activated killer cell-originated protein kinase.
Zhao S; Cui J; Cao L; Han K; Ma X; Chen H; Yin S; Zhao C; Ma C; Hu H
Phytother Res; 2023 Jul; 37(7):3057-3068. PubMed ID: 36882184
[TBL] [Abstract][Full Text] [Related]
20. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
